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For the past few decades, obesity and its closely 
associated co-morbidities, such as type II diabetes 
mellitus have shown a steady rise among all age groups, 
from the adolescents to elderly. Several factors, 
including early diet-associated neuronal rewiring and 
epigenetic modifications, were suggested to lead to 
metabolic disturbances later in life [1–3]. While many 
peripheral metabolism regulating sites, such as pancreas 
and liver have been well studied, the central pathways, 
sensing glucose and affecting insulin production, 
feeding and energy expenditure, remain discordantly 
less explored. Within the brain, the hypothalamus, and 
its several nuclei, including the Arcuate Nucleus 
(ARC), Paraventricular Nucleus  (PVN),  Preoptic  Area  
 
(POA), and others, possess multiple features implicated 
in the control of glucose homeostasis [4,5]. The 
fenestrated vasculature grants hypothalamus with direct 
exposure to the arterial blood carrying nutrients, as well 
as hormones such as insulin, leptin, ghrelin, translating 
these peripheral cues to adaptive physiological 
responses. For example, central administration of 
insulin provokes hyperpolarization of ARC-residing 
AgRP and POMC neurons [6], whereas neuron-specific 
ablation of insulin receptors is associated with diet-
induced obesity [7], and ablation from AgRP, but not 
POMC neurons, alters hepatic glucose production [8,9]. 
Beyond hormonal cues, glucose itself appears to 
function not only as fuel, but also as a signaling 
molecule within the hypothalamus. Neurons and 
astroglia express high levels of GLUT2 and low affinity 



















The  ventral  hypothalamus  (VHT)  integrates  several  physiological  cues  to maintain  glucose  homeostasis  and
energy  balance.  Aging  is  associated  with  increased  glucose  intolerance  but  the  underlying  mechanisms
responsible for age‐related metabolic decline, including neuronal signaling in the VHT, remain elusive. We have
shown  that mice with VHT‐targeted overexpression of ∆FosB, a splice variant of  the AP1  transcription  factor
FosB, exhibit  increased energy expenditure,  leading to decreased adiposity. Here, we show that VHT‐targeted
overexpression  of  ∆FosB  also  improves  glucose  tolerance,  increases  insulin  sensitivity  in  target  organs  and
thereby  suppresses  insulin  secretion.    These  effects  are  also  observed  by  the  overexpression  of  dominant
negative JunD, demonstrating that they occur via AP1 antagonism within the VHT. Furthermore, the improved
glucose  tolerance  and  insulin  sensitivity  persisted  in  aged  animals  overexpressing  ∆FosB  in  the  VHT.  These
beneficial effects on glucose metabolism were abolished by peripheral sympathectomy and α‐adrenergic, but
not β‐adrenergic, blockade. Taken together, our results show that antagonizing AP1 transcription activity in the
VHT  leads to a marked  improvement  in whole body glucose homeostasis via activation of the SNS, conferring
protection against age‐related impairment in glucose metabolism. These findings may open novel avenues for
therapeutic intervention in diabetes and age‐related glucose intolerance.  
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hexokinase, which allows them to sense glucose and the 
ATP/AMP ratio [10,11]. This sensing leads to a rapid 
cessation of feeding following intraventricular injection 
of glucose, via excitation or inhibition of neuronal 
activity [12].  
 
Although the exact mechanisms of central regulation of 
glucose homeostasis are only partially elucidated, it is 
known that hypothalamic neurons activate the 
sympathetic (SNS) and parasympathetic (PNS) 
branches of the autonomous nervous system, which 
control insulin and glucagon secretion [13], as well as 
pancreatic β-and α-cell number [14]. Noradrenergic 
SNS endings are associated with insulin suppression, 
while PNS endings, containing mainly acetylcholine, 
confer an opposite effect of induced insulin secretion. 
Inactivation of GLUT2 from neurons, was demonstrated 
to lower β-cell proliferation, suppress PNS tone, and 
lead to an overall glucose intolerance. Moreover, the 
hypothalamus is known to exert SNS-dependent 
regulation of brown fat thermogenic activity, which is 
implicated in the regulation of whole body glucose 
metabolism [15]. This complex machinery, relying on 
multiple factors aimed at containing glucose within 
strict levels, deteriorates with aging, and with aging-
related neurodegenerative disorders [16].   
 
Interestingly, the role of aforementioned factors, 
including insulin and leptin, is not restricted to the 
regulation of glucose, but governs energy expenditure, 
adiposity and glucose homeostasis as a whole.  In 
previous studies we have shown that transgenic mice 
expressing ΔFosB, a naturally occurring splice isoform 
of the AP1 transcription factor FosB, under the control 
of broad enolase 2 (ENO2) promoter exhibit a 
phenotype of increased energy metabolism, enhanced 
glucose handling and reduced adiposity [17–20]. 
ΔFosB, which lacks the C-terminal transactivation 
domain, behaves as an AP1 antagonist [21]. In attempt 
to identify the site of action, we targeted ΔFosB, or the 
artificial AP1 antagonist dominant-negative JunD 
(DNJunD), selectively to the ventral hypothalamus 
(VHT) of mice by means of stereotaxic viral delivery 
and recapitulated energy and fat phenotypes observed in 
ENO2-ΔFosB model [18,20]. In this study, we aimed to 
explore whether the effects on adiposity and energy 
expenditure of centrally delivered ΔFosB are: 1. 
Associated with changes in whole body glucose 
metabolism; 2. Affect glucose metabolism through the 
course of aging. Furthermore, we set to investigate the 
mechanism by which these metabolic effects are 
mediated.  Our data demonstrate that VHT over-
expression of ΔFosB improves glucose profile, and is 
associated with increased glucose tolerance and insulin 
sensitivity in the peripheral organs.  These effects 
persist in aged animals, conferring protection against 
age-related decline in insulin sensitivity and increased 
adiposity.  Finally, we show that central ΔFosB 
influences glucose metabolism via SNS, by a 
mechanism involving α-, but not β-adrenergic receptors 
(AR).  These findings opens roadway for future search 




Site-specific overexpression of ∆FosB in the ventral 
hypothalamus 
 
To examine the effects of central ΔFosB on whole body 
glucose homeostasis we utilized our previously 
established method of stereotaxically-assisted, virally-
mediated gene transfer, where AAV-ΔFosB or AAV-
GFP (control) are injected bilaterally into the VHT of 
adult mice. To validate the specificity of the induced 
expression, mice received stereotaxic injections of 
either AAV-ΔFosB or AAV-GFP in the right 
hemisphere and saline in the left hemisphere (sham) 
(Fig. 1A). GFP expression was observed in the VHT of 
both AAV-GFP- and AAV-ΔFosB-injected sides, but 
not on the sham-injected side. ΔFosB protein 
expression, as assessed by immunostaining, was 
observed only in the AAV-ΔFosB-injected side where it 
co-localized with GFP fluorescence (Fig. 1A). Western 
blotting confirmed ΔFosB overexpression in the hypo-
thalamus (Fig. 1B). Overall, these data demonstrate our 
ability to deliver ΔFosB specifically to the VHT. 
 
Overexpression of ΔFosB in the ventral 
hypothalamus improves glucose metabolism despite 
a lower insulin response to glucose 
 
To characterize the effects of VHT-overexpressed 
ΔFosB on glucose metabolism, several tests were 
performed. First, we measured blood glucose and 
insulin levels in mice injected with AAV-ΔFosB or 
AAV-GFP (control) at the age of 7-8 weeks and 
analyzed 8 weeks post-surgery. Glucose and insulin 
levels at both fasted and fed state were lower in the 
AAV-ΔFosB group compared to control (Fig. 2A,B). 
The glucose tolerance test (GTT) showed that AAV-
ΔFosB injected mice displayed lower glucose levels 
following an i.p. glucose bolus than control (Fig. 2C), 
suggesting better glucose tolerance. Contrary to our 
expectations, the improved glucose tolerance was not 
due to increased insulin levels: the AAV-ΔFosB group 
revealed significantly lower insulin levels during GTT 
(Fig. 2D), suggesting that the observed increased 
glucose tolerance might be due to higher insulin 
sensitivity. In agreement with this hypothesis, 
pancreatic islets of AAV-ΔFosB mice were markedly 
smaller in size than those of control, as evident from 
insulin immunostaining and morphometric analysis 
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(Fig. 2E,F). Examination of gene expression in isolated 
islets showed decreased insulin 2, Pdx-1 and Ki-67 
mRNA levels in AAV-ΔFosB mice compared to AAV-
GFP mice, whereas there were no changes in insulin 1 
and glucagon mRNAs (Fig. 2G). Since reduction in Pdx1 
expression in pancreatic β-cells has been linked with an 
increased rate of apoptotic cell death [32, 33], possibly 
explaining the small islets, we then tested whether AAV-
ΔFosB islets displayed a dysfunction in glucose-
stimulated insulin secretion (GSIS). Surprisingly, despite 
smaller islet size and reduced Pdx-1 expression, the GSIS 
test performed on isolated AAV-ΔFosB pancreatic islets 
showed a dose-dependent increase in both basal insulin 
level and glucose-stimulated insulin secretion compared 
to control (Fig. 2H). This induction of insulin secretion in 
islets isolated from AAV-ΔFosB mice is in contrast with 
the observed suppression of insulin secretion in response 
to glucose bolus in the same mice. This suggests that the 
suppressed in vivo insulin response due to VHT ΔFosB 




































Supporting this concept, ΔFosB overexpression in the 
pancreatic MIN-6 cell line failed to induce insulin (Fig. 
2I). Taken together, these results support the ability of 
central ΔFosB to stimulate whole body glucose uptake, 
when overexpressed in the VHT. 
 
Overexpression of ΔFosB in the ventral 
hypothalamus increases insulin sensitivity in the 
periphery 
 
Improved glucose tolerance despite a lower insulin 
response in AAV-ΔFosB mice suggests increased 
insulin sensitivity. Thus, we next examined whether 
VHT-ΔFosB overexpressing mice exhibit altered insulin 
sensitivity in peripheral tissues, in addition to the 
pancreatic elevated ability to secrete insulin. 
Confirming our earlier observations [20], body weight 
and visceral epididymal fat pad weight were significant-
ly lower in the AAV-ΔFosB mice than in control mice 
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that AAV-ΔFosB mice exhibited a greater decrease in 
plasma glucose levels in response to insulin and a lower 
AUC (Fig. 3C), suggesting a higher efficacy of insulin 
in clearing glucose from the circulation. Accordingly, 
the insulin resistance index (HOMA-IR) was found to 
be almost two-fold lower in AAV-ΔFosB group than 

















































Finally, providing further evidence in support of 
increased insulin sensitivity, we found increased 
relative level of phosphorylated AKT in skeletal muscle 
and in interscapular brown adipose tissue (BAT) in 
mice with VHT-ΔFosB overexpression (Fig. 3E). Taken 
together, these data suggest that expression of ΔFosB in 


















































Figure 2. VHT overexpression of  ΔFosB  improves glucose profile despite  lower  insulin  response. Mice were
stereotaxically  injected  into VHT with AAV‐ΔFosB or AAV‐GFP and  glucose metabolism  assessed 8 weeks post‐surgically
(n=8). (A) Fasted and fed glucose levels (B) Fasted and fed insulin levels (C) GTT glucose (D) GTT insulin (E) Immunostaining
of  pancreas with  anti‐insulin  antibody.  Scale  bar;  200μm.  (F) Histomorphometry  of  insulin‐stained  pancreatic  islets  (G).
qPCR analysis of isolated pancreatic islets. (H) GSIS test of isolated pancreatic islets from AAV‐GFP and AAV‐ΔFosB mice. (I)
GSIS test of MIN‐6 cells transfected with ΔFosB.  Data are presented as mean ± SEM. *p<0.05, **p<0.01. 









































The improvement of insulin sensitivity precedes the 
reduction in visceral adiposity 
 
Multiple studies outline the positive effect of weight 
loss and % body fat reduction on glucose metabolism in 
both healthy individuals and individuals with metabolic 
syndrome [22]. Given the smaller fat pad size in 
transgenic ENO2-ΔFosB [18] as well as in VHT-
overexpressing AAV-ΔFosB models (Fig. 3B), we then 
determined whether the increase in insulin sensitivity 
was secondary to the reduction in visceral adiposity.  
For this purpose, we investigated the glucose responses 
to ΔFosB hypothalamic overexpression at an earlier 
time point after injection (2 weeks), a time at which the 
energy metabolism and fat effects are not yet 









































ΔFosB showed no change in body weight and visceral 
fat pad weight from the control (Fig. 4A, B). Likewise, 
AAV-ΔFosB mice displayed no improved reduction in 
glucose and insulin levels in the GTT (Fig. 4C,D). At 
the same time point however, despite no apparent 
reduction in weight or fat, ITT demonstrated lower 
glucose levels (Fig. 4E), similar HOMA-IR (Fig. 4F), 
both indicating initiation of higher insulin sensitivity at 
this time point. Finally, increased insulin-induced Akt 
phosphorylation in skeletal muscle was already 
observed in AAV-ΔFosB mice at this time point (Fig. 
4G). Taken together, these results suggest that the 
increase in insulin sensitivity in AAV-ΔFosB mice is 
not a secondary effect of the reduction in visceral fat, 
but rather the result of direct neuronal regulation 
downstream of hypothalamic ΔFosB. 
Figure 3. VHT overexpression of ΔFosB  increases  insulin sensitivity  in the periphery.  Mice were stereotaxically  injected
into  VHT  with  AAV‐ΔFosB  or  AAV‐GFP  and  insulin  response  was  assessed  8  weeks  post‐surgically  (n=8).  (A)  Body  weight  (B)
Abdominal epididymal fat pad weight (C) ITT, data are presented as percentage of initial blood glucose concentration (D) HOMA‐IR (E)
Western blotting of Akt phospholylation in skeletal muscle and brown fat (BAT).  Data are presented as mean ± SEM. *p<0.05, p<0.01. 













































ΔFosB exerts its favorable effects on glucose 
metabolism via AP1 antagonism 
 
AP1 transcriptional activity is dependent upon the 
heterodimerization between Fos and Jun proteins, with 
antagonistic properties inferred by ΔFosB [21]. 
However, ΔFosB acts as a mixed agonist-antagonist of 
AP1 in vitro and in vivo [23], making it difficult to 
















































have previously shown that AAV-driven hypothalamic 
overexpression of DNJunD, an artificial pure AP1 
antagonist, increases energy expenditure and reduces fat 
to a similar extent as ΔFosB [20], demonstrating that it 
is the effects of ΔFosB are due to its antagonism to 
AP1. We therefore determined whether antagonism of 
AP1 transcriptional activity in the ventral hypothalamus 
is responsible for the improved glucose metabolism 
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reporter assay of various combinations of FosB and 
JunD isoforms on 6X TRE-luciferase in the mouse 
hypothalamic cell line mHypoE42 [24]. When ΔFosB 
or DNJunD was paired with their active binding 
partners - FosB or JunD - luciferase activity was 
decreased (Fig. 5A). ΔFosB/DNJunD heterodimer 
combination displayed the least reporter activity, 
















































gonists to AP1 transactivation in hypothalamic cells. 
Next, we examined glucose metabolism response in mice 
carrying stereotaxically delivered AAV-DNJunD in the 
VHT. Similar to AAV-ΔFosB mice, AAV-DNJunD 
mice exhibited lower fed glucose and insulin levels, 
lower glucose levels in response to glucose bolus, 
despite suppressed insulin response during GTT, and 
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IR showed only a trend towards reduced insulin 
resistance (Fig. 5G), ITT revealed greater insulin 
sensitivity compared to control (Fig. 5F).  Collectively, 
analysis of VHT DNJunD overexpressing mice 
demonstrated an improved glucose metabolism profile 
comparable to the one observed in VHT ΔFosB mice.  
These results suggest that ΔFosB mediates its metabolic 

















































AAV-ΔFosB mice are resistant to age-related 
adiposity and impairment in glucose metabolism 
 
During aging, mammals frequently develop impaired 
glucose tolerance and insulin resistance [16].   So far 
our analysis was focused on young animals with normal 
metabolic profile, yet it was important to delineate 
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vulnerable metabolic conditions, such as those observed 
with aging. To address this question we performed 
metabolic analysis on aged mice overexpressing VHT 
AAV-ΔFosB or AAV-GFP (control) injection, 40 
weeks post-surgically, at the age of 48 weeks. Both 
AAV-ΔFosB and control groups exhibited marked 
accumulation of body weight and abdominal adiposity, 
as compared to younger mice (Fig. 6A,B). In contrast, 
















































dominal adiposity than AAV-GFP mice (Fig. 6B). GTT 
analysis revealed that at time zero, aged AAV-GFP 
mice showed higher insulin levels than their younger 
AAV-GFP counterparts, 1.56±0.31 ng/mL vs 0.41±0.08 
ng/mL respectively (Fig. 6C and Fig. 2D), suggesting 
the development of age-related hyperinsulinemia. In 
contrast, the increase in insulinemia in aged AAV-
ΔFosB mice was very moderate (0.58±0.12 ng/mL vs 
















































Figure 7.  The  SNS blockade diminishes  the VHT  ΔFosB‐mediated  improvement  in  glucose  tolerance  and
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Similarly, aged AAV-∆FosB mice continued having 
significantly lower levels of glucose and insulin during 
the GTT (Fig. 6C,D). Furthermore, the ITT showed that 
while aged AAV-GFP mice developed insulin 
resistance compared to younger AAV-GFP mice, as 



















































6E and Fig. 3C), aged AAV-ΔFosB mice maintained 
higher insulin sensitivity. Taken together, these results 
indicate that ΔFosB overexpression in the VHT 
prevents age-related abdominal adiposity and plays a 
protective role against the glucose intolerance and 
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The VHT ΔFosB-mediated improvement in glucose 
tolerance and insulin sensitivity are dependent on 
the SNS 
 
As outlined in the introduction, central regulation of 
glucose and energy metabolism employs both hormonal 
and neuronal relays. SNS projections linking the hypo-
thalamus to the endocrine pancreas are known to 
directly affect insulin production and secretion [13,14]. 
We therefore hypothesized that the SNS may be 
involved in mediating the improvements in glucose 
metabolism induced by VHT ΔFosB overexpression in 
older mice. To test this hypothesis, we performed 
peripheral sympathectomy in AAV-ΔFosB and AAV-
GFP (control) mice by administering the catecho-
laminergic neurotoxin 6-hydroxydopamine (6-OHDA), 
which enter cells via monoamine transporters, leading 
to sympathetic neuronal degeneration [25]. Analysis of 
glucose metabolism revealed that the SNS neuro-
degeneration induced by 6-OHDA completely abolished 
the reduction in glucose blood levels, despite lower 
insulin, following GTT in AAV-ΔFosB mice as 
compared to AAV-GFP control, suggesting that glucose 
tolerance and insulin sensitivity triggered by central 
ΔFosB requires an intact SNS (Fig. 7A,B).  Moreover, 
as expected, vehicle-treated AAV-ΔFosB showed 
increased insulin sensitivity compared to the vehicle-
treated AAV-GFP group, whereas 6-OHDA-treated 
AAV-ΔFosB and AAV-GFP mice had comparable 
glucose responses to insulin injection (Fig. 7C).  
Collectively, these data demonstrate the essential role of 
the SNS in mediating the increase in glucose tolerance 
and in insulin sensitivity induced by ΔFosB expression 
in the VHT. 
 
ΔFosB overexpressed in the VHT regulates insulin 
secretion and insulin sensitivity via α-, but not β 
adrenergic receptor in aged mice   
 
On the pancreatic α-cells, norepinephrine binds to β2-
adrenergic receptor (β2-AR), which stimulates glucagon 
secretion, whereas on β-cells it binds to α2-AR, which 
inhibits insulin secretion [13]. Given the essential role 
of SNS in mediating the metabolic effect of ΔFosB in 
older mice and the increased epinephrine and 
norepinephrine levels in aged AAV-ΔFosB mice (Fig. 
8A,B), we next attempted to block ARs to determine 
whether it would have an effect on glucose and insulin 
profile. Phentolamine and propranolol are commonly 
used as general α- and β-AR blockers, respectively. 
Aged AAV-GFP and AAV-ΔFosB mice were pretreated 
with either agent and subjected to metabolic evaluation. 
Interestingly, phentolamine-treated AAV-ΔFosB mice 
showed identical glucose and insulin levels during GTT 
to phenotolamine-treated AAV-GFP control mice (Fig. 
8C,E), suggesting that α-AR activation is essential for 
conferring the central ΔFosB effect on glucose 
homeostasis. On the other hand, propranolol-treated 
AAV-ΔFosB mice maintained their significantly lower 
glucose and insulin levels compared to AAV-GFP mice 
(Fig. 8D,F) suggesting that β-AR blockade does not 
interfere with central ΔFosB action. While increased 
insulin sensitivity was persistent in propranolol-treated 
AAV-∆FosB group, phentolamine-treated AAV-GFP 
and AAV-ΔFosB groups were both resistant to 
exogenous insulin probably due to the severe hyper-
insulinemia induced by pretreatment of phentolamine 
(Fig. 8E,G,H). Surprisingly, phentolamine-treated AAV- 
ΔFosB group showed increased glucose levels at the 
later time points, 60 and 120 min, possibly suggesting 
an increased insulin-independent glucose uptake via α-
AR in this group. Taken together, α-adrenergic 
signaling, but not β-adrenergic signaling, plays a critical 
role in regulating insulin secretion as well as glucose 
clearance in response to increased expression of ΔFosB 




The experimental evidence presented in this paper 
highlights the role of hypothalamic AP1 trans-
criptional machinery in the regulation of glucose 
homeostasis in both young and aged mice.  We have 
shown that restricted expression of ΔFosB in the VHT, 
which comprises, among others, ARC and PVN nuclei, 
exerts beneficial effects not only on bone [17–20], but 
also on metabolic homeostasis, both in terms of 
glucose metabolism and adiposity, which persist with 
aging.  
 
One of the most striking effects of ΔFosB expression in 
the VHT is the extreme reduction in the size of 
pancreatic islets, which occurs in parallel with the 
marked decrease in insulin secretion in response to 
glucose. This reduction in insulin-producing cells and in 
insulin secretion could be the result of the marked 
increase in insulin sensitivity we observed in target 
organs and/or the result of direct neuronal influences on 
the pancreas. Our data clearly establish the fact that 
these changes occur before and independently of the 
reduction in body fat, which is therefore most likely be 
the consequence rather than the cause of the improved 
glucose metabolism. Furthermore, our results establish 
clearly that the effects of ΔFosB on glucose metabolism 
are mediated by the SNS, and more specifically by 
activation of the α-AR pathway, since the effect on 
glucose handling can be blocked by α-AR, but not β-AR 
inhibition. Lastly, we show that these ΔFosB-mediated 
effects render aged mice resistant to age-related 
adiposity and impairment in glucose metabolism. 
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Metabolic homeostasis relies on the carefully weighted 
balance between the blood levels of glucose and insulin, 
and excess/deficit of either factor may trigger a 
pathological outcome.  For example, if insulin 
sensitivity is increased without a corresponding 
correction of insulin release, blood glucose levels 
remain unbalanced and patients ultimately suffer from 
weight gain [26]. In similar fashion, advanced type II 
diabetes is often presented with chronically low insulin 
secretion on the background of receding insulin 
sensitivity, resulting in suboptimal clearance of glucose 
from the blood. Recent genomic analysis in humans and 
rodents revealed that the gain of function mutation in 
α2A-AR, is linked to reduced insulin secretion which 
also occurs in absence of enhanced sensitivity and thus 
predisposes the development of diabetes [27]. In contrast 
to the above scenario, in our studies, suppressed insulin 
secretion did not lead to diabetes and instead, coincided 
with a robust increase in insulin sensitivity in target 
organs, which favored the establishment of balanced 
glucose homeostasis. Since short-term treatment with α-
AR blocker phentolamine was sufficient to completely 
abolish the insulin sensitivity phenotype caused by 
hypothalamic FosB, as evident from the ITT, yet was 
not long enough to affect the islet size, we conclude that 
the effects on insulin secretion and islet reduction, are 
secondary to the effects on insulin sensitivity. Our data 
suggests that central AP-1 blockade triggers an 
integrative, favorably balanced metabolic response, 
where activation of α-AR results in higher insulin 
sensitivity, driving reduction in the size of the pancreatic 
islets to maintain the balance between the capacity to 
produce insulin and the reduced need of insulin. 
 
Beyond insulin secretion, α-AR stimulation of 
adrenomedullary chromaffin cells activates a negative 
feedback loop, which further limits the release of 
adrenaline/noradrenaline and thus functions to suppress 
SNS tone [28–30]. From a clinical perspective, 
enhanced sympathetic activity coincides with the 
metabolic syndrome, and on the other hand, weight loss 
is associated with toning down of the SNS [29]. While 
the literature strongly supports the inverse relationship 
between SNS activation and glucose handling, an 
emerging body of work suggests that SNS innervation 
of brown fat (BAT) exerts a contrastingly positive effect 
on glucose handling and energy expenditure [15,31]. 
Recent studies have shown that BAT control of glucose 
utilization is orchestrated by SNS-sensitive uncoupling 
protein 1 (UCP1) and glucose transporter 4 (GLUT4) 
[32] and this activation is at least in part linked to the 
activity of hypothalamic AgRP neurons [33].   
 
It has been well recognized that a subgroup of neurons 
in the hypothalamus are capable of sensing glucose and 
influencing blood glucose levels by regulating the 
secretion of anti-insulin hormones and hepatic glucose 
production [34,35]. The AP1 family member c-fos is a 
proto-oncogene that is rapidly expressed within some 
neurons following depolarization, such that c-fos 
expression is widely used as a marker for neuronal 
activation [36,37]. This induction of c-fos is also seen in 
the process of glucose sensing in the hypothalamus. 
Hypoglycemia or central glucoprivation increases c-fos 
expression in a number of hypothalamic nuclei, 
including the ARC, the paraventricular and dorsomedial 
nuclei and the lateral hypothalamus [38]. In contrast to 
hypoglycemia, little is known about glucose sensing 
neurons during hyperglycemia. It is reported that central 
glucose infusion via the carotid artery increased c-fos 
expression in ARC and paraventricular nucleus neurons, 
leading to transient peripheral insulin secretion [39]. It 
is therefore reasonable to speculate that ∆FosB 
overexpression in the VHT may play a role in 
regulating glucose sensing in the VHT neurons and 
subsequent insulin secretion since ∆FosB is expected to 
also antagonize c-fos-dependent AP1 signaling and has 
been shown to desensitize c-fos expression via 
chromatin remodeling at the c-fos gene promoter [23].  
 
During aging and aging-associated neurodegenerative 
disorders, the markers of metabolic derangement, such 
as inflammation and insulin resistance, leading to 
suppressed glucose uptake, are present both at the 
periphery [40] and in the CNS neuronal circuits [41,42]. 
Indeed, the prevalence of diabetes in older adults is more 
than 25% in the US population and more than twice that 
of middle-aged adults [43]. Age-related decline in insulin 
sensitivity has been attributed to various factors including 
increased abdominal adiposity. The chronic activation of 
the peripheral SNS has been shown to associate with 
aging. It is considered to be initiated by increased 
adiposity and in order to expend excess energy as heat by 
β-AR thermogenesis. This however eventually evolves 
into a mechanism that facilitates further development of 
adiposity by desensitization of β-ARs. Therefore, 
suppression of age-related adiposity may play a critical 
role in preventing and/or delaying the progression of 
metabolic decline with age.  
 
Collectively, our results show that antagonizing AP-1 
transcriptional activity by ∆FosB, the naturally occurring 
splice isoform of FosB, in the VHT leads to a profound 
improvement in whole body glucose homeostasis via the 
SNS α-adrenergic pathway. Importantly, these effects 
persist with aging in mice, conferring protection against 
the age-related decline in glucose metabolism. Our 
observations suggest that targeting the AP1 pathway may 
offer potential means for improvement not only of 
skeletal homeostasis, but also of whole body glucose 
homeostasis, preventing not only the development of age-
related bone loss but also glucose intolerance. 





Male C57BL6/J mice were purchased from the Jackson 
Laboratory and housed in a temperature controlled 
(25°C) environment under a 12-hour light/dark cycle 
and fed a rodent chow diet (5058, Pico Lab). All animal 
protocols were approved by the Harvard University 
Institutional Animal Care and Use Committee. 
 
Stereotaxic injections into the VHT 
 
Adeno-associated viruses encoding either ΔFosB-ires-
GFP, DNJunD (an N-terminal Δ1–149aa truncation of 
JunD)-IRES-GFP or ires-GFP alone were injected 
bilaterally into the ventral hypothalamus of male 
C57BL/6J mice at 7-8 weeks old weighing 23 - 27g. 
Stereotaxic coordinates of the injection site were 
anterior-posterior -2.1 mm, lateral ± 1.3 mm, and 
dorsal-ventral -5.8 mm at an angle of 10° from Bregma. 
Animals were analyzed 8-9 weeks after injections, 
unless noted otherwise.  
 
Injection validation and analysis of ΔFosB 
expression 
 
For the purpose of injection validation, saline was 
injected one side as a sham control and either AAV-GFP 
or AAV-ΔFosB on the other side of the ventral 
hypothalamus (Fig. 1A).  For further validation of protein 
expression, whole brain was dissected and separated into 
three parts: A - anterior part to the coronal cut at the optic 
chiasm; Hy – hypothalamus; and P - posterior part to the 
cut at mammillary body; and then subjected to 
subsequent protein analysis by immunoblotting (Fig. 1B). 
The hypothalamus was dissected by making two coronal 
cuts at anterior border of the optic chiasm and the 
posterior border of the mammillary body, a horizontal cut 
at the anterior commissure, and two saggital cuts 1.5 mm 
from the midline.  
 
Histological analysis of pancreas 
 
Pancreas were collected, fixed overnight in 3.7% PBS-
buffered formaldehyde, embedded in paraffin and 
sectioned at 5 μm. Sections were immunostained for β-
cells using rabbit anti-insulin polyclonal antibody 
(4590, Cell Signaling) and counterstained with 
hematoxylin. Quantitative histomorphometric analysis 
of islet area and number was performed using Image J 
software (National Institute of Health). 
 
Glucose and insulin tolerance test 
 
Glucose tolerance test (GTT)  was  performed  by  admi- 
nistrating glucose (2.0 mg/g BW) intraperitoneally after a 
16-hour fast. Blood glucose levels were monitored using 
glucose test strips and a glucometer (OneTouch ultra, 
LifeScan) at indicated times. Blood was also collected 
from tails using EDTA-treated microcapillaries and 
plasma insulin levels were measured using an EIA kit 
(ALPCO).  For insulin tolerance test (ITT), mice were 
fasted for 4 hours and injected insulin (1.0 mU/g BW, 
Lilly) intraperitoneally, and blood glucose levels were 
measured at indicated times.  
 
Immunofluorescent staining  
 
Mice were perfused with saline for 10 min and then 
3.7% PBS-buffered formaldehyde for 30 min. Whole 
brains were taken out and post fixed overnight in 3.7% 
PBS-buffered formaldehyde and then cryoprotected for 
36 hours in 20 % sucrose. Brains were then embedded 
in OCT compound (Tissue Tek), sectioned at 25 μm. 
ΔFosB immunofluorescence staining was performed 
with rabbit anti-ΔFosB monoclonal antibody (9890, 
Cell Signaling) followed by goat anti-rabbit IgG Alexa-
fluo-568 conjugated antibody (A11011, Thermo Fischer 
Scientific). Nuclear staining was done using SlowFade 
Gold antifade reagent with DAPI (Invitrogen). 
 
Isolation of primary pancreatic islets  
 
Primary islets were isolated using an intraductal 
collagenase technique [28]. Briefly, after clamping the 
common bile duct at its entrance to the duodenum, 
pancreas was injected with 3 ml of a collagenase P 
(1mg/ml, Roche) solution in M199 media (Sigma). 
Dissected pancreas was then digested for 17 min at 
37°C, after which they were disrupted by shaking for 30 
seconds. Islets were subsequently purified through 100 
μm wire mesh and Histopaque 1077 (Sigma) density 
centrifugation. Islets were cultured for 1-2 hours at 
37°C in RPMI 1640 media (Sigma) supplemented with 
10% FBS (26140, Life Technologies), 1% Penicillin 
and Streptomycin (Life Technologies), handpicked 
under inverted bright-field microscopy, and allowed to 
recover overnight at 37°C and 5% CO2. Islets were 
serum and glucose starved (2.8 mM glucose RPMI 1640 
without FBS) for 2 hours and then stimulated with 2.8 
mM and 25 mM glucose for 1 hour. 
 
AKT phosphorylation  
 
24-hour fasted mice were i.p. injected with insulin (5 
mU/g BW, Lilly) or PBS as vehicle control. 15 minutes 
later, mice were euthanized and skeletal muscle and fat 
samples were dissected. Samples were then subjected to 
western blot analysis using rabbit anti-phospho AKT 
(Ser473) and rabbit anti-pan AKT monoclonal 
antibodies (4060 and 4691, Cell Signaling).  
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Tissue samples were lysed with modified RIPA buffer 
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1% Triton-X-100, 0.1% SDS, 1 mM 
phenylmethylsulfonyl fluoride) supplemented with 
protease and phosphatase inhibitor cocktails (Roche). 
Protein concentrations were determined using BCA kit 
(Thermo Scientific). Protein samples were separated by 
4-15% SDS-PAGE and transferred to nitrocellulose 
membranes using Trans-Blot Turbo transfer system 
(BioRad). Membranes were then blocked with 5% skim 
milk in TBS and incubated with primary antibodies 
overnight at 4 °C. Membranes were then washed with 
TBST and incubated with HRP-linked anti-rabbit IgG 
(7074, Cell Signaling) for 1 h and washed with TBST. 
Immunoreactivities were assessed using ECL plus kit 
(Perkin Elmer). Membranes were stripped using 
stripping buffer (Clontech) and reused for β-actin 
detection (4970, Cell Signaling).  
 
MIN-6 cell culture and in vitro glucose-stimulated 
insulin secretion test 
 
A mouse pancreatic β cell line, MIN-6 was a kind gift 
from Dr. Jun-ichi Miyazaki (Osaka University) and Dr. 
Donald F. Steiner (University of Chicago). MIN-6 cells 
are derived from mouse insulinoma cells and displays 
characteristics of pancreatic β-cells, including glucose-
stimulated insulin secretion [44].  MIN-6 cells were 
plated at a density of 2 X 105 cells per well in 12-well 
plates and maintained in DMEM with 4.5g/L glucose 
and L-glutamine (D5648, Sigma) supplemented with 
3.7g/L sodium bicarbonate, 5μ/L β- mercaptoethanol, 
10% Fetal Bovine Serum (FBS, 26140, Life 
Technologies) and 1% Penicillin Streptomycin (Life 
Technologies) at 37°C and 5% CO2. At 40-50 % 
confluency, cells were transfected using X-tremeGENE 
HP (Roche) with either pcDNA3.1 (Life Technologies) 
as an empty control or pcΔFosB at the amount of 0.5 μg 
per well. 4 Days after transfection at about 90 % 
confluency, cells were serum and glucose starved (2.8 
mM glucose DMEM without FBS) for 2 hours and then 
stimulated with 2.8 and 11.2 mM glucose DMEM 
without FBS for 1 hour. Media from each well was 
removed and used to determine insulin levels using an 
EIA kit (ALPCO).  
 
Urinary catecholamine levels 
 
Urine was collected from conscious mice for 5-7 
consecutive days and pooled. Epinephrine and 
norepinephrine levels were measured using BiCAT kit 
(ALPCO). Epinephrine and norepinephrine levels were 
then normalized by urinary creatinine levels measured 
by an enzymatic colorimetric method (Stanbio). 
Luciferase assays 
 
Embryonic mouse hypothalamic mHypoE 42 cells were 
plated at a density of 0.5 X 105 cells per well in 12-well 
plates and maintained in DMEM with 10% FBS (26140, 
Life Technologies) and 1% Penicillin Streptomycin 
(Life Technologies) at 37°C and 5% CO2. 24 hours after 
seeding, cells were co-transfected using X-tremeGENE 
HP (Roche) with a construct encoding 6X-TRE-firefly 
luciferase reporter (Clontech) and with a construct 
encoding a JunD isoform (pcJunD or pcDNJunD) and a 
constract encoding a FosB isoform (pcFosB or 
pcΔFosB) to measure AP-1 activity. Transfection 
efficiency was assessed by co-transfecting a TK Renilla 
luciferase construct (Promega). 36 hours after 
transfection, a dual luciferase assay (Dual-Glo 
Luciferase Assay System, Promega) was performed 
according to the manufacturer’s instructions. 
 
Peripheral sympathectomy with 6-OHDA  
 
To induce peripheral sympathectomy, mice received 
intraperitoneal (i.p.) injections of 6-hydroxydopamine 
(6-OHDA, Sigma) at doses of 100 mg/kg BW on day -5 
and 250 mg/kgBW on day -3. Vehicle group received 
the solvent, 0.02% ascorbic acid in saline on each day. 
After stereotaxic surgery to inject AAV-GFP or AAV-
ΔFosB in VHT was performed on day 0, mice received 
biweekly (every two weeks) i.p. injections of 6-OHDA 
or vehicle. Mice were subjected to metabolic tests after 
third biweekly i.p. injection (day 42) then euthanized 
for analysis.  
 
Adrenergic receptor blockade 
 
To study the effect of α-adrenergic and β-adrenergic 
signaling on glucose metabolism, mice were pretreated 
intraperitoneally with 10 mg/kgBW phentolamine 
(Sigma) and 5 mg/kgBW propranolol (Sigma) 30 
minutes before glucose and insulin challenge at GTT 




Results are given as mean ± SEM. Statistical analysis 
were performed using unpaired 2-tailed Student’s t test 
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